1.Gelenberg, AJ, Dunner, DL, Rothschild, AJ, Pedersen, R, Dorries, KM, Ninan, PT.Sexual functioning in patients with recurrent major depressive disorder enrolled in the PREVENT study. J Nerv Ment Dis. 2013; 201(4): 266–273.
2.Ishak, WW, Christensen, S, Sayer, G, et al.Sexual satisfaction and quality of life in major depressive disorder before and after treatment with citalopram in the STAR*D study. J Clin Psychiatry. 2013; 74(3): 256–261.
3.Montejo, AL, Llorca, G, Izquierdo, JA, Rico-Villademoros, F.Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction. J Clin Psychiatry. 2001; 62 Suppl 3: 10–21.
4.Williams, VS, Edin, HM, Hogue, SL, Fehnel, SE, Baldwin, DS.Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010; 24(4): 489–496.
5.Clayton, AH, Pradko, JF, Croft, HA, et al.Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry. 2002; 63(4): 357–366.
6.Serretti, A, Chiesa, A.Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009; 29(3): 259–266.
7.Clayton, A, Kornstein, S, Prakash, A, Mallinckrodt, C, Wohlreich, M.Changes in sexual functioning associated with duloxetine, escitalopram, and placebo in the treatment of patients with major depressive disorder. J Sex Med. 2007; 4(4 Pt 1): 917–929.
8.Ashton, AK, Rosen, RC.Accommodation to serotonin reuptake inhibitor-induced sexual dysfunction. J Sex Marital Ther. 1998; 24(3): 191–192.
9.Delgado, PL, Brannan, SK, Mallinckrodt, CH, et al.Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry. 2005; 66(6): 686–692.
10.Hu, XH, Bull, SA, Hunkeler, EM, et al.Incidence and duration of side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatment for depression: patient report versus physician estimate. J Clin Psychiatry. 2004; 65(7): 959–965.
11.Williams, VS, Baldwin, DS, Hogue, SL, Fehnel, SE, Hollis, KA, Edin, HM.Estimating the prevalence and impact of antidepressant-induced sexual dysfunction in 2 European countries: a cross-sectional patient survey. J Clin Psychiatry. 2006; 67(2): 204–210.
12.Duenas, H, Lee, A, Brnabic, AJ, et al.Frequency of treatment-emergent sexual dysfunction and treatment effectiveness during SSRI or duloxetine therapy: 8-week data from a 6-month observational study. Int J Psychiatry Clin Pract. 2011; 15(2): 80–90.
13.Pratt, L, Brody, D, Gu, Q. Antidepressant Use Among Persons Aged 12 and Over: United States, 2011–2014. NCHS Data Brief No. 283, August 2017. Hyattsville, MD: National Center for Health Statistics; 2017.
14.Chokka, PR, Hankey, JR.Assessment and management of sexual dysfunction in the context of depression. Ther Adv Psychopharmacol. 2018; 8(1): 13–23.
15.Jacobsen, PL, Mahableshwarkar, AR, Chen, Y, Chrones, L, Clayton, AH.Effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015; 12(10): 2036–2048.
16.Rothschild, AJ.Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995; 152(10): 1514–1516.
17.Clayton, AH, Warnock, JK, Kornstein, SG, Pinkerton, R, Sheldon-Keller, A, McGarvey, EL.A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction. J Clin Psychiatry. 2004; 65(1): 62–67.
18.Taylor, MJ, Rudkin, L, Bullemor-Day, P, Lubin, J, Chukwujekwu, C, Hawton, K.Strategies for managing sexual dysfunction induced by antidepressant medication. Cochrane Database Syst Rev. 2013; 2013(5): CD003382.
19.Bang-Andersen, B, Ruhland, T, Jorgensen, M, et al.Discovery of 1-2-(2, 4-dimethylphenylsulfanyl)phenyl.piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011; 54(9): 3206–3221.
20.Westrich, L, Pehrson, A, Zhong, H, et al.In vitro and in vivo effects for the multimodal antidepressant vortioxetine (Lu AA21004) at human and rat targets. Int J Psychiatry Clin Pract. 2012; 16(S1): 47.
21.Trintellix package insert. Deerfield, IL: Takeda Pharmaceuticals America, Inc.; 2016.
22.Baldwin, DS, Loft, H, Dragheim, M.A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 2012; 22(7): 482–491.
23.Boulenger, JP, Loft, H, Olsen, CK.Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 2014; 29(3): 138–149.
24.Henigsberg, N, Mahableshwarkar, AR, Jacobsen, P, Chen, Y, Thase, ME.A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 2012; 73(7): 953–959.
25.Jain, R, Mahableshwarkar, AR, Jacobsen, P, Chen, Y, Thase, ME.A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(2): 313–321.
26.Mahableshwarkar, AR, Jacobsen, PL, Chen, Y.A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013; 29(3): 217–226.
27.Jacobsen, PL, Mahableshwarkar, AR, Chen, Y, Chrones, L, Clayton, AH.effect of vortioxetine vs. escitalopram on sexual functioning in adults with well-treated major depressive disorder experiencing SSRI-induced sexual dysfunction. J Sex Med. 2015; 12(10): 2036–2048.
28.Guy, W.The Clinician Global Severity and Impression Scales: ECDEU Assessment Manual for Psychopharmacology. DHEW Publication no. 76–338. Rockville, MD: National Institute of Mental Health; 1976: 218–222.
29.Keller, A, McGarvey, EL, Clayton, AH.Reliability and construct validity of the Changes in Sexual Functioning Questionnaire short-form (CSFQ-14). J Sex Marital Ther. 2006; 32(1): 43–52.
30.Clayton, AH, Hamilton, DV.Female sexual dysfunction. Psychiatr Clin North Am. 2010; 33(2): 323–338.
31.Bulloch, A, Williams, J, Lavorato, D, Patten, S.Recurrence of major depressive episodes is strongly dependent on the number of previous episodes. Depress Anxiety. 2014; 31(1): 72–76.
32.Feldman, HA, Goldstein, I, Hatzichristou, DG, Krane, RJ, McKinlay, JB.Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994; 151(1): 54–61.
33.Clayton, AH, Gommoll, C, Chen, D, Nunez, R, Mathews, M.Sexual dysfunction during treatment of major depressive disorder with vilazodone, citalopram, or placebo: results from a phase IV clinical trial. Int Clin Psychopharmacol. 2015; 30(4): 216–223.
34.Salazar, DE, Frackiewicz, EJ, Dockens, R, et al.Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. J Clin Pharmacol. 2001; 41(12): 1351–1358.
35.Rickels, K, Athanasiou, M, Robinson, DS, Gibertini, M, Whalen, H, Reed, CR.Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2009; 70(3): 326–333.